logo

For the Inventor, By the Inventor

Wuppertal, Germany

Klaus-Dieter Bremm

This inventor holds 39 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignee: Bayer Aktiengesellschaft. Active years: 1993-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Klaus-Dieter Bremm. Retrieved from https://idiyas.com/inventor/klaus-dieter-bremm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 39

% Patents Active = 89.7

Average Co-Inventor Count = 7.4

ph-index = 11

Forward Citations = 383(Granted Patents)


Location History:

  • Dortmund, DE (1994)
  • Recklinghausen, DE (1996 - 2005)
  • Wuppertal, DE (1993 - 2007)

Company Filing History:

goldMedal39 out of 12,268 
 
Bayer Aktiengesellschaft
 patents

Years Active: 1993-2007

Loading Chart...
Areas of Expertise:
Cholesterol Inhibitors
Tetrahydroquinolines
Quinolone Derivatives
Naphthyridone Compounds
Cycloalkano-Pyridines
Bicyclic-Fused Pyridines
Heterocyclic Compounds
Cephalosporins
Pharmaceutical Compositions
Hyperlipoproteinaemia
Medicinal Chemistry
Drug Development
39 patents (USPTO):Explore Patents
1. 7192971 - 4-Heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein (2007-03-20),
2. 6958346 - 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein (2005-10-25),
3. 6897317 - 4-Phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein (2005-05-24),
4. 6586613 - Substituted tetrahydronaphthaline and analogous compounds (2003-07-01),
5. 6562976 - 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein (2003-05-13),
6. 6387929 - 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein (2002-05-14),
7. 6291477 - Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia (2001-09-18),
8. 6207671 - Cycloalkano-pyridines (2001-03-27),
9. 6121330 - 5-Hydroxyalkyl substituted phenyls and their use in medicaments for the (2000-09-19),
10. 6069160 - Heteroatom-containing benzocyclopentane-oxazolidinones (2000-05-30),
11. 6069148 - Cycloalkano-pyridines (2000-05-30),
12. 6063788 - Bicyclic-fused pyridines (2000-05-16),
13. 6018054 - 7-isoindolinyl-quinolone derivatives and 7-isoindolinyl-naphthyridone (2000-01-25),
14. 6015666 - Rapid DNA test for detecting quinolone-resistant Staphylococcus aureus (2000-01-18),
15. 5932587 - Heterocyclic-fused pyridines (1999-08-03),

Title: The Innovative Journey of Klaus-Dieter Bremm

Introduction

Klaus-Dieter Bremm, based in Wuppertal, Germany, is a prolific inventor with an impressive portfolio of 39 patents to his name. His contributions to the field of medicinal chemistry, particularly in the treatment of cardiovascular diseases, have established him as a notable figure in innovation.

Latest Patents

Among his latest innovations are the patents related to 4-Heteroaryl-tetrahydroquinolines, which are recognized for their role as inhibitors of the cholesterin-ester transfer protein. These hetero-tetrahydroquinolines can be synthesized by condensing substituted hetero-tetrahydroquinoline aldehydes or by reducing keto-substituted variants, thereby facilitating the introduction of desired substituents through established methods. The significance of these compounds lies in their potential application as active ingredients in medications aimed at treating atherosclerosis and dyslipidemias.

Career Highlights

Klaus-Dieter Bremm's professional journey includes significant tenures at Bayer Aktiengesellschaft, a renowned pharmaceutical company. His extensive work has paved the way for advancements in drug development, with a focus on innovative solutions for complex health issues.

Collaborations

Throughout his career, Klaus-Dieter has collaborated with esteemed colleagues such as Rainer Endermann and Uwe Petersen. These partnerships have been instrumental in fostering a collaborative approach towards research and development, contributing to groundbreaking inventions and patents.

Conclusion

Klaus-Dieter Bremm's dedication to innovation in medicinal chemistry has not only led to a substantial number of patents but has also made a lasting impact on the medical field. His work exemplifies how inventive solutions can address critical health challenges, paving the way for future breakthroughs in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…